Mylan NV disclosed that its chairman received nearly $100 million last year, among the largest pay packages disclosed this year for any public company, even as the drugmaker was buffeted in 2016 by a public furor over hefty price increases on its lifesaving EpiPen.
The disclosed pay for Robert J. Coury doesn’t include an additional $66.3 million in retirement benefits and other payments that Coury received last year in connection with what Mylan called his transition from executive chairman to a nonemployee chairman role.
